Results 341 to 350 of about 39,039 (378)
Some of the next articles are maybe not open access.
Bispecific antibodies in cancer therapy
Current Opinion in Immunology, 1999Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
George J. Weiner +2 more
openaire +2 more sources
Bispecific Antibodies as Novel Bioconjugates
Bioconjugate Chemistry, 1998Bispecific antibodies are unique macromolecular heterobifunctional cross-linkers with two different binding specificities within a single molecule. As ideal bioconjugates, they can specifically glue any two different molecules together without the need for chemical conjugation.
Mavanur R. Suresh, Y Cao
openaire +3 more sources
Bispecific antibodies in oncology
Nature Reviews Drug Discovery, 2022Arman, Esfandiari +2 more
openaire +2 more sources
Bispecific antibodies in haematological malignancies
Cancer Treatment Reviews, 2018Bispecific antibodies (bsAbs) combine the binding sites of two monoclonal antibodies in one molecule. The close proximity of a tumor specific antigen and an effector cell antigen results in a targeted activation of effector cells. The mechanism is similar to the chimeric antigen receptor (CAR) T-cells, recently approved in two haematologic cancers. CAR
Ralf C. Bargou, Andreas Viardot
openaire +3 more sources
Chemical Production of Bispecific Antibodies
2004This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Paul Guptill, Robert F. Graziano
openaire +3 more sources
Bispecific antibody conjugates in therapeutics
Advanced Drug Delivery Reviews, 2003Bispecific monoclonal antibodies have drawn considerable attention from the research community due to their unique structure against two different antigens. The two-arm structure of bsMAb allows researchers to place a therapeutic agent on one arm while allowing the other to specifically target the disease site.
Ying Cao, Laura Lam
openaire +3 more sources
Biotechnology Progress, 2018
Production of knob and hole dual light chain bispecific antibodies poses several unique challenges for development of a feasible industrial scale manufacturing process. We developed an efficient process for the assembly and purification of knob and hole dual light chain bispecific antibodies.
Glen Giese +3 more
openaire +3 more sources
Production of knob and hole dual light chain bispecific antibodies poses several unique challenges for development of a feasible industrial scale manufacturing process. We developed an efficient process for the assembly and purification of knob and hole dual light chain bispecific antibodies.
Glen Giese +3 more
openaire +3 more sources
Bispecific antibodies rise again
Nature Reviews Drug Discovery, 2014Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire +3 more sources
Producing Bispecific and Bifunctional Antibodies
2004Bispecific antibodies are artificially engineered monoclonal antibodies (MAbs) that consist of two distinct binding sites and are capable of binding two different antigens noncovalently. They can be produced by chemical cross-linkage, genetic engineering, or somatic hybridization.
Mavanur R. Suresh, Dipankar Das
openaire +3 more sources
Bispecific Antibody Therapy in Hemophilia
New England Journal of Medicine, 2017Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire +3 more sources